Palvella Therapeutics Announces Expansion of QTORIN(TM) Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
(NASDAQ:PVLA), Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients Company plans to initiate a Phase 2 trial evaluating QTORIN(TM) rapamycin for clinically significant angiokeratomas in the second half of 2026 Company to host […]